(BMRN) Biomarin Pharmaceutical - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 10.014m USD | Total Return: -12.8% in 12m

Enzyme Therapies, Growth Treatments, Gene Therapies, Metabolic Treatments
Total Rating 38
Safety 80
Buy Signal -0.30
Biotechnology
Industry Rotation: -6.3
Market Cap: 10.0B
Avg Turnover: 86.9M
Risk 3d forecast
Volatility31.4%
VaR 5th Pctl5.17%
VaR vs Median0.00%
Reward TTM
Sharpe Ratio-0.35
Rel. Str. IBD18
Rel. Str. Peer Group14.2
Character TTM
Beta0.458
Beta Downside0.461
Hurst Exponent0.440
Drawdowns 3y
Max DD48.02%
CAGR/Max DD-0.37
CAGR/Mean DD-0.67
EPS (Earnings per Share) EPS (Earnings per Share) of BMRN over the last years for every Quarter: "2021-03": 0.09, "2021-06": 0.07, "2021-09": -0.2, "2021-12": -0.32, "2022-03": 0.18, "2022-06": 0.15, "2022-09": -0.04, "2022-12": -0.0013, "2023-03": 0.27, "2023-06": 0.29, "2023-09": 0.21, "2023-12": 0.18, "2024-03": 0.46, "2024-06": 0.56, "2024-09": 0.55, "2024-12": 0.92, "2025-03": 1.13, "2025-06": 1.44, "2025-09": 0.12, "2025-12": 0.46, "2026-03": 0.76,
EPS CAGR: 54.14%
EPS Trend: 66.3%
Last SUE: -0.36
Qual. Beats: 0
Revenue Revenue of BMRN over the last years for every Quarter: 2021-03: 486.03, 2021-06: 501.693, 2021-09: 408.742, 2021-12: 449.81, 2022-03: 519.359, 2022-06: 533.798, 2022-09: 505.344, 2022-12: 537.538, 2023-03: 596.415, 2023-06: 595.275, 2023-09: 581.329, 2023-12: 646.207, 2024-03: 648.833, 2024-06: 712.029, 2024-09: 745.74, 2024-12: 747.313, 2025-03: 745.145, 2025-06: 825.41, 2025-09: 776.133, 2025-12: 874.565, 2026-03: 766.208,
Rev. CAGR: 10.12%
Rev. Trend: 95.4%
Last SUE: 0.56
Qual. Beats: 0

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: BMRN Biomarin Pharmaceutical

BioMarin Pharmaceutical Inc. (BMRN) specializes in the development and commercialization of enzyme replacement therapies and molecular treatments for rare genetic diseases. The company’s portfolio targets lysosomal storage disorders, growth conditions like achondroplasia, and metabolic diseases including phenylketonuria. Its global distribution network serves specialty pharmacies, hospitals, and government agencies across North America, Europe, and the Asia-Pacific region.

The biotechnology sector often utilizes an orphan drug business model, which provides regulatory exclusivity and high pricing power for treatments targeting small patient populations. BioMarin maintains a robust pipeline of oligonucleotides and long-acting peptides to address unmet needs in pediatric growth and muscular dystrophy. Investors might consider reviewing ValueRay for deeper insights into the companys valuation metrics.

Founded in 1996 and headquartered in San Rafael, California, the company operates through strategic licensing and collaboration agreements to expand its international reach. By focusing on life-threatening conditions with limited competition, BioMarin leverages specialized manufacturing processes to maintain its market position within the rare disease niche.

Headlines to Watch Out For
  • Voxzogo global sales expansion drives long-term revenue growth and market share gains
  • Roctavian commercial uptake remains slow amid high treatment costs and payer hurdles
  • Vimizim and Naglazyme provide stable cash flows as core enzyme replacement therapies
  • Research and development pipeline progress offsets generic competition for legacy product Kuvan
  • Operational restructuring and margin expansion initiatives influence investor sentiment and profitability targets
Piotroski VR‑10 (Strict) 5.0
Net Income: 268.7m TTM > 0 and > 6% of Revenue
FCF/TA: 0.09 > 0.02 and ΔFCF/TA 0.25 > 1.0
NWC/Revenue: 117.6% < 20% (prev 96.25%; Δ 21.31% < -1%)
CFO/TA 0.10 > 3% & CFO 874.3m > Net Income 268.7m
Net Debt (-782.8m) to EBITDA (482.5m): -1.62 < 3
Current Ratio: 5.81 > 1.5 & < 3
Outstanding Shares: last quarter (197.7m) vs 12m ago 0.61% < -2%
Gross Margin: 75.93% > 18% (prev 0.79%; Δ 7.51k% > 0.5%)
Asset Turnover: 41.20% > 50% (prev 41.28%; Δ -0.08% > 0%)
Interest Coverage Ratio: 17.77 > 6 (EBITDA TTM 482.5m / Interest Expense TTM 23.0m)
Altman Z'' 3.47
A: 0.44 (Total Current Assets 4.61b - Total Current Liabilities 793.2m) / Total Assets 8.59b
B: 0.03 (Retained Earnings 259.7m / Total Assets 8.59b)
C: 0.05 (EBIT TTM 408.6m / Avg Total Assets 7.87b)
D: 0.11 (Book Value of Equity 255.7m / Total Liabilities 2.38b)
Altman-Z'' Score: 3.47 = A
Beneish M -2.92
DSRI: 1.11 (Receivables 903.9m/739.2m, Revenue 3.24b/2.95b)
GMI: 1.05 (GM 75.93% / 79.44%)
AQI: 0.95 (AQ_t 0.35 / AQ_t-1 0.37)
SGI: 1.10 (Revenue 3.24b / 2.95b)
TATA: -0.07 (NI 268.7m - CFO 874.3m) / TA 8.59b)
Beneish M-Score: -2.92 (Cap -4..+1) = A
What is the price of BMRN shares? As of May 18, 2026, the stock is trading at USD 51.81 with a total of 2,075,391 shares traded.
Over the past week, the price has changed by -4.16%, over one month by -5.18%, over three months by -13.58% and over the past year by -12.79%.
Is BMRN a buy, sell or hold? Biomarin Pharmaceutical has received a consensus analysts rating of 4.34. Therefore, it is recommended to buy BMRN.
  • StrongBuy: 16
  • Buy: 7
  • Hold: 6
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the BMRN price?
Analysts Target Price 89.5 72.8%
Biomarin Pharmaceutical (BMRN) - Fundamental Data Overview as of 17 May 2026
P/E Trailing = 37.2734
P/E Forward = 10.8578
P/S = 3.0886
P/B = 1.682
P/EG = 0.4679
Revenue TTM = 3.24b USD
EBIT TTM = 408.6m USD
EBITDA TTM = 482.5m USD
Long Term Debt = 1.43b USD (from longTermDebt, last quarter)
Short Term Debt = 9.32m USD (from shortTermDebt, last quarter)
Debt = 1.44b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -782.8m USD (from netDebt column, last quarter)
Enterprise Value = 9.23b USD (10.01b + Debt 1.44b - CCE 2.22b)
Interest Coverage Ratio = 17.77 (Ebit TTM 408.6m / Interest Expense TTM 23.0m)
EV/FCF = 12.03x (Enterprise Value 9.23b / FCF TTM 767.1m)
FCF Yield = 8.31% (FCF TTM 767.1m / Enterprise Value 9.23b)
FCF Margin = 23.66% (FCF TTM 767.1m / Revenue TTM 3.24b)
Net Margin = 8.29% (Net Income TTM 268.7m / Revenue TTM 3.24b)
Gross Margin = 75.93% ((Revenue TTM 3.24b - Cost of Revenue TTM 780.3m) / Revenue TTM)
Gross Margin QoQ = 74.55% (prev 66.26%)
Tobins Q-Ratio = 1.07 (Enterprise Value 9.23b / Total Assets 8.59b)
Interest Expense / Debt = 1.04% (Interest Expense 15.0m / Debt 1.44b)
Taxrate = 25.27% (35.7m / 141.2m)
NOPAT = 305.4m (EBIT 408.6m * (1 - 25.27%))
Current Ratio = 5.81 (Total Current Assets 4.61b / Total Current Liabilities 793.2m)
Debt / Equity = 0.23 (Debt 1.44b / totalStockholderEquity, last quarter 6.21b)
Debt / EBITDA = -1.62 (Net Debt -782.8m / EBITDA 482.5m)
Debt / FCF = -1.02 (Net Debt -782.8m / FCF TTM 767.1m)
Total Stockholder Equity = 6.10b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.42% (Net Income 268.7m / Total Assets 8.59b)
RoE = 4.41% (Net Income TTM 268.7m / Total Stockholder Equity 6.10b)
RoCE = 5.43% (EBIT 408.6m / Capital Employed (Equity 6.10b + L.T.Debt 1.43b))
RoIC = 4.42% (NOPAT 305.4m / Invested Capital 6.90b)
WACC = 6.73% (E(10.01b)/V(11.45b) * Re(7.59%) + D(1.44b)/V(11.45b) * Rd(1.04%) * (1-Tc(0.25)))
Discount Rate = 7.59% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (quarterly) Correlation: -4.84 | Cagr: 1.38%
[DCF] Terminal Value 85.85% ; FCFF base≈708.3m ; Y1≈873.8m ; Y5≈1.49b
[DCF] Fair Price = 183.0 (EV 34.58b - Net Debt -782.8m = Equity 35.37b / Shares 193.3m; r=6.73% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 66.31 | EPS CAGR: 54.14% | SUE: -0.36 | # QB: 0
Revenue Correlation: 95.42 | Revenue CAGR: 10.12% | SUE: 0.56 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.97 | Chg30d=+5.20% | Revisions=+0% | Analysts=13
EPS next Quarter (2026-09-30): EPS=1.46 | Chg30d=+3.04% | Revisions=-20% | Analysts=13
EPS current Year (2026-12-31): EPS=4.91 | Chg30d=-8.00% | Revisions=-17% | GrowthEPS=+56.0% | GrowthRev=+20.2%
EPS next Year (2027-12-31): EPS=6.67 | Chg30d=-0.94% | Revisions=+0% | GrowthEPS=+35.8% | GrowthRev=+14.5%
[Analyst] Revisions Ratio: -20%